Status:

UNKNOWN

Characteristics of LKDS and PBSS of KOA Based on the Enhancement of Inflammatory Response by TGF-β/Smad Pathway Inhibited

Lead Sponsor:

Dongzhimen Hospital, Beijing

Conditions:

Knee Osteoarthritis

Syndrome

Eligibility:

All Genders

20-80 years

Brief Summary

1. Through research and analysis, the levels of upstream and downstream factors related to TGF-β/Smad signaling pathway and inflammatory response factor related factors in serum, blood cells, articula...

Detailed Description

1. Through research and analysis, the levels of upstream and downstream factors related to TGF-β/Smad signaling pathway and inflammatory response factor related factors in serum, blood cells, articula...

Eligibility Criteria

Inclusion

  • Inclusion criteria of liver and kidney deficiency syndrome and phlegm and blood stasis syndrome in knee osteoarthritis
  • Age 20-80 years old, in line with the diagnostic criteria of Western medicine;
  • In accordance with the diagnostic criteria of TCM syndromes, it belongs to liver and kidney deficiency syndrome and phlegm and blood stasis syndrome;
  • Patients who are willing to participate in the survey and have good compliance;
  • Voluntary signing of informed consent;
  • Inclusion criteria of normal control group
  • Age 20-80 years old.
  • Patients who are willing to participate in the survey and have good compliance.
  • It does not meet the diagnostic criteria of knee osteoarthritis.
  • Voluntarily sign informed consent.

Exclusion

  • Complications affecting joints, such as psoriasis, syphilitic neuropathy, brown yellow disease, metabolic bone disease, etc;
  • There were rheumatoid arthritis and ankylosing spondylitis;
  • Late disabled and incapacitated;
  • Pregnant or lactating women;
  • Mentally ill.
  • As long as one of the above 5 articles is met, it shall be excluded.

Key Trial Info

Start Date :

December 24 2021

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

December 31 2024

Estimated Enrollment :

340 Patients enrolled

Trial Details

Trial ID

NCT05218122

Start Date

December 24 2021

End Date

December 31 2024

Last Update

February 1 2022

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Dongzhimen Hospital

Beijing, Beijing Municipality, China, 100700